These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 38397092)
1. Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies. Liao YM; Hsu SH; Chiou SS Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397092 [TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions. Salaroli A; Spilleboudt C; Bron D; Lewalle P Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231 [TBL] [Abstract][Full Text] [Related]
3. Coengineering specificity, safety, and function into T cells for cancer immunotherapy. Giordano Attianese GMP; Ash S; Irving M Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063 [TBL] [Abstract][Full Text] [Related]
4. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631 [TBL] [Abstract][Full Text] [Related]
5. CAR T-Cell Therapy in Hematological Malignancies. Haslauer T; Greil R; Zaborsky N; Geisberger R Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities. Ho M; Zanwar S; Paludo J Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132 [TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
8. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Can I; Cox MJ; Siegler EL; Sakemura R; Kenderian SS Exp Hematol; 2022 Apr; 108():1-7. PubMed ID: 35150777 [TBL] [Abstract][Full Text] [Related]
9. Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Tang L; Huang ZP; Mei H; Hu Y Mil Med Res; 2023 Nov; 10(1):52. PubMed ID: 37941075 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
11. Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights. Pu Z; Wang TB; Mou L Front Immunol; 2023; 14():1310285. PubMed ID: 38090577 [TBL] [Abstract][Full Text] [Related]
12. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. Qin Y; Xu G Front Immunol; 2022; 13():1053120. PubMed ID: 36569859 [TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Maus MV; Levine BL Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942 [TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Badar T; Shah NN Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in CAR-T cell engineering. Huang R; Li X; He Y; Zhu W; Gao L; Liu Y; Gao L; Wen Q; Zhong JF; Zhang C; Zhang X J Hematol Oncol; 2020 Jul; 13(1):86. PubMed ID: 32616000 [TBL] [Abstract][Full Text] [Related]
16. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R Front Immunol; 2022; 13():903562. PubMed ID: 35720364 [TBL] [Abstract][Full Text] [Related]
17. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies. Kim SJ; Yoon SE; Kim WS Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527 [TBL] [Abstract][Full Text] [Related]
18. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
19. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026 [TBL] [Abstract][Full Text] [Related]
20. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]